Our technologies overcome a key challenge in precision medicine: that disease pathway and immune cell activation can only be inferred (often imprecisely) through surrogate measures such as genetic status or levels of protein expression. Now these critical information may be gleaned readily by the SH2S-MS analysis
Precision Proteomics Value-Add
- Drug target and biomarker discovery: Identify or validate novel drug targets (e.g., tyrosine kinases or immuno-regulators) and biomarkers (e.g., phosphoproteins, phosphorylation clusters or signatures) associated with disease conditions or responses to therapy in cell lines, animal models or clinical samples.
- Drug and clinical assay development: Assess the efficacy, mechanism of action and off-target effects for TK-targeting therapies and immunotherapies in cell lines, animal models or clinical samples.
- Subgroup analysis of trial readouts: Identify pTyr-based signatures for subgroup categorization (e.g., profiling of responders and non-responders to drug).
- Companion & molecular diagnostic development: Characterize TK activations in the tumor of individual patients prior to treatment, for correlation to outcome from therapy. Diagnostic mass spectrometry-derived TK activation signatures can form the basis of a new class of clinical assays or can be obtained with conventional techniques using SH2S-enabled enrichment.
- Development strategy for combo therapies: Global TK profiling to characterize kinome programing/reprogramming associated with acquired resistance or relapse in order to inform investigations into combination strategies for existing therapies and therapeutic candidates.